CEO Executive AssistantReal-world evidence has moved from the periphery of pharmaceutical strategy to its center. Payers are demanding RWE before making formulary decisions. Regulatory agencies are accepting RWE for label expansions and safety updates. Health technology assessment bodies are requiring real-world data to inform cost-effectiveness assessments. And pharmaceutical companies are increasingly using RWE to demonstrate product value in ways that clinical trial data alone cannot.
For pharmaceutical CEOs, RWE strategy is genuinely CEO-level work: deciding which evidence gaps are most critical to business success, allocating significant resources to evidence generation programs, and ensuring that RWE strategy is integrated with commercial, regulatory, and medical affairs priorities. But the operational dimensions of RWE, including study design, data acquisition, analytical execution, and publication, require specialized expertise that is best managed by a dedicated team.
This guide gives pharmaceutical CEOs a practical delegation framework for RWE that captures the CEO’s strategic value while building the operational capability that generates compelling evidence.
The Strategic Case for CEO Engagement in RWE
Before defining the delegation model, it is worth understanding why RWE strategy deserves CEO-level strategic engagement.
Market access is increasingly evidence-dependent. Major pharmacy benefit managers and insurance companies have significantly raised their evidence expectations for formulary decisions, particularly for high-cost specialty drugs. Companies without robust RWE programs face formulary restrictions that directly limit patient access and revenue.
Label expansion opportunities require RWE. The FDA’s Real-World Evidence Framework has opened pathways for using RWE to support label expansion applications. CEOs who invest in RWE infrastructure can pursue label expansions that competitors without RWE capabilities cannot.
Long development timelines require anticipation. RWE programs take two to five years from study design to publication. Evidence needed for a 2030 payer negotiation must be initiated in 2025 or 2026. Strategic anticipation of evidence needs is genuinely CEO-level work because it requires resource allocation commitments years before the evidence will be deployed.
Competitive differentiation. In therapeutic areas where multiple products compete for the same patient population, RWE that demonstrates real-world effectiveness, safety, and economic value can be a significant commercial differentiator.
The CEO’s RWE Strategic Role
The CEO’s direct involvement in RWE is appropriately limited to strategic decisions that require CEO-level authority and judgment.
Evidence investment prioritization. The CEO should approve the annual RWE investment plan, setting priorities for evidence generation across the product portfolio. This requires understanding which products face the most significant evidence gaps and which evidence investments will generate the greatest market access or commercial return.
Regulatory RWE strategy. When the company is considering using RWE in a regulatory submission, whether for label expansion, safety updates, or post-marketing commitments, the CEO should be engaged in the strategic decision about the regulatory RWE approach.
Major data partnerships. Significant data partnerships with health systems, payers, or data companies to access electronic health records, claims data, or other RWE data sources require senior leadership approval and in some cases CEO-level relationship management.
Investor communication on RWE strategy. Investors and analysts increasingly evaluate pharmaceutical companies’ RWE capabilities as a proxy for market access confidence. The CEO must be able to discuss RWE strategy fluently in investor settings.
Delegating RWE Operations
A dedicated RWE team within the outcomes research or HEOR function should own all operational dimensions of the RWE program.
VP of Real-World Evidence or Head of Outcomes Research. This leader owns RWE strategy and operations: identifying evidence gaps, prioritizing RWE studies, managing data partnerships, overseeing study execution, and ensuring that RWE findings are communicated effectively to payers, regulators, and physicians.
RWE epidemiologists and data scientists. Specialists in observational study design, pharmacoepidemiology, and health data analytics should own study design, protocol development, data analysis, and statistical methods for RWE programs.
Data access and partnerships. A data partnerships manager or team should own relationships with data providers: negotiating data access agreements, managing data quality assessment, and coordinating data governance compliance.
RWE regulatory specialists. For programs where RWE is intended for regulatory use, regulatory affairs specialists with RWE expertise should own the regulatory strategy and submission management.
RWE publications and communications. A publications manager or team should own the dissemination of RWE findings: managing the publication pipeline, developing payer-ready evidence summaries, and coordinating conference presentations.
For a broader framework on delegating commercial and evidence strategy in pharma, see our resource on pharma commercial strategy.
RWE Study Design and Protocol Development
Study design is where the quality of RWE is determined. Observational studies are subject to confounding, selection bias, and other methodological limitations that must be addressed through careful study design and analytical approach.
RWE epidemiologists and biostatisticians should own study design: developing protocols, selecting appropriate study designs, addressing confounding through statistical methods, and pre-registering studies where appropriate. External scientific advisory boards and academic collaborators can provide methodological guidance.
The CEO is not involved in study design decisions. The CEO’s role is to ensure that the RWE team has the methodological expertise and external advisory relationships needed to design studies that will be credible to payers, regulators, and the scientific community.
Data Governance and Privacy Compliance
RWE programs involve the use of patient data from electronic health records, claims databases, patient registries, and other sources. Managing this data responsibly requires robust governance and privacy compliance.
A data governance function, working with legal and compliance teams, should own RWE data governance: establishing policies for data access and use, ensuring compliance with HIPAA and other privacy regulations, managing data use agreements, and conducting privacy impact assessments for new data programs.
The CEO ensures that organizational data governance policies reflect the company’s values around patient privacy and that adequate resources are invested in compliance. Operational data governance management belongs with compliance and legal professionals.
RWE and Market Access Integration
The primary commercial purpose of most RWE programs is to support market access: giving payers evidence of real-world effectiveness, safety, and economic value that supports formulary decisions. Ensuring that RWE programs generate evidence that is actually useful for payer negotiations requires close coordination between the RWE team and the market access function.
A joint RWE-market access planning process, led by the heads of RWE and market access, should define the specific evidence questions that payers are asking, prioritize RWE studies to address those questions, and establish timelines for evidence generation that align with payer engagement milestones.
The CEO reviews and approves the integrated evidence plan as part of annual strategic planning, ensuring adequate resourcing and strategic alignment across RWE and market access functions.
Real-World Evidence for Label Expansion
The FDA’s framework for using real-world evidence in regulatory decision-making has created significant opportunities for label expansion based on observational data. Pursuing these opportunities requires both scientific rigor and regulatory expertise.
A cross-functional team including RWE specialists, regulatory affairs, and clinical development should own label expansion RWE strategy: identifying expansion opportunities where RWE could support a regulatory case, designing studies that will meet FDA methodological standards, and managing FDA interactions throughout the process.
The CEO engages when major label expansion decisions require senior leadership commitment, including decisions about significant study investments or major regulatory strategies. Operational management of the label expansion process belongs with the cross-functional team.
Investigator-Initiated Studies and Academic Partnerships
Pharmaceutical companies often support investigator-initiated studies, where academic researchers design and conduct studies using company products, as a mechanism for generating independent RWE. Managing these programs requires a balance between supporting good science and maintaining appropriate company interest boundaries.
A medical affairs or RWE team should own the IIS program: receiving and reviewing applications, managing the grants committee process, providing appropriate support to funded investigators, and tracking study progress and publications.
The CEO ensures that the IIS program is governed with genuine independence from commercial objectives and that funded investigators have the academic freedom needed to produce credible independent research.
Building RWE Capabilities for the Long Term
RWE capability is not built quickly. Data access relationships require negotiation. Methodological expertise requires recruitment and development. The publication of credible RWE takes years from study initiation to peer review.
The CEO who begins investing in RWE capabilities before the company faces urgent evidence needs is building a competitive advantage that will compound over time. The CEO who waits until a major payer negotiation is approaching to invest in RWE will find that the evidence needed does not exist.
According to McKinsey and Company, pharmaceutical companies with mature RWE capabilities achieve significantly better market access outcomes and higher formulary success rates than those without established RWE programs.
Communicating RWE Results
RWE findings must be communicated to multiple audiences: payers who need economic and outcomes evidence, physicians who need real-world efficacy and safety data, regulators who need evidence packages for label decisions, and investors who need confidence in the product’s real-world performance.
Each audience requires a different communication approach. Payer-facing RWE communications should focus on formulary decision-relevant evidence: cost-effectiveness, budget impact, and comparative effectiveness. Physician-facing communications should focus on real-world clinical outcomes, safety in broader populations, and appropriate use guidance. The RWE publications and communications team owns these differentiated communication strategies.
The CEO communicates about RWE strategy at the organizational level in investor, board, and major external stakeholder settings, supported by materials the RWE team prepares.
For guidance on integrating RWE into the drug pipeline delegation model, see our resource on pharma drug pipeline.
The pharmaceutical CEO who builds a robust RWE capability and maintains strategic oversight of the evidence portfolio while delegating operational RWE management is building one of the most durable competitive advantages available in modern pharmaceutical strategy. The evidence base that results will serve the organization across commercial negotiations, regulatory interactions, and investor communications for years to come.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.